Cwm LLC Sells 879 Shares of Qiagen (NYSE:QGEN)

Cwm LLC lowered its holdings in shares of Qiagen (NYSE:QGEN) by 31.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,878 shares of the company’s stock after selling 879 shares during the period. Cwm LLC’s holdings in Qiagen were worth $82,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Panagora Asset Management Inc. grew its holdings in Qiagen by 66.1% during the 3rd quarter. Panagora Asset Management Inc. now owns 60,648 shares of the company’s stock valued at $2,456,000 after buying an additional 24,144 shares in the last quarter. Alaska Permanent Fund Corp purchased a new position in Qiagen during the third quarter valued at $1,582,000. Xponance Inc. increased its holdings in Qiagen by 9.1% in the 3rd quarter. Xponance Inc. now owns 9,356 shares of the company’s stock valued at $379,000 after acquiring an additional 780 shares during the last quarter. ING Groep NV lifted its stake in Qiagen by 28.4% in the 3rd quarter. ING Groep NV now owns 257,392 shares of the company’s stock worth $10,424,000 after purchasing an additional 56,901 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Qiagen by 16.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 255,837 shares of the company’s stock valued at $10,361,000 after purchasing an additional 35,297 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Up 0.9 %

NYSE QGEN opened at $42.95 on Wednesday. The company has a quick ratio of 1.45, a current ratio of 1.84 and a debt-to-equity ratio of 0.25. Qiagen has a 52 week low of $34.74 and a 52 week high of $47.70. The firm has a market capitalization of $9.80 billion, a price-to-earnings ratio of 28.80, a PEG ratio of 3.64 and a beta of 0.42. The company has a fifty day moving average of $42.50 and a two-hundred day moving average of $42.83.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. The firm had revenue of $459.00 million during the quarter, compared to analyst estimates of $453.91 million. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. Qiagen’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same period last year, the company earned $0.53 EPS. On average, analysts predict that Qiagen will post 2.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on QGEN shares. Stifel Nicolaus reduced their target price on Qiagen from $55.00 to $45.00 and set a “hold” rating on the stock in a report on Wednesday, May 1st. Citigroup reduced their price objective on Qiagen from $61.86 to $60.00 and set a “buy” rating on the stock in a research note on Thursday, February 8th. Morgan Stanley raised shares of Qiagen from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $49.48 to $51.00 in a report on Friday, February 16th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Qiagen from $50.00 to $52.00 and gave the stock an “overweight” rating in a research report on Thursday, February 8th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $50.95.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.